Novo Nordisk Needs Answers to These 5 Key Questions
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and ...
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Investing27m
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional ...